How Atorvastatin Inhibits Cholesterol Synthesis
Atorvastatin, sold as Lipitor, is a statin that lowers cholesterol by blocking HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate in the liver—the rate-limiting step of cholesterol biosynthesis.[1] This reduces hepatic cholesterol production by up to 50% at standard doses, prompting the liver to increase LDL receptor expression on cell surfaces.[1][2]
What Happens Upstream and Downstream in the Pathway
The mevalonate pathway starts with acetyl-CoA and branches into cholesterol, bile acids, and non-sterol products like coenzyme Q10. Atorvastatin competitively inhibits HMG-CoA reductase (Ki around 7 nM), depleting intracellular cholesterol pools.[2] Low cholesterol triggers SREBP-2 activation, upregulating LDL receptors to clear circulating LDL from blood (reducing serum LDL by 40-60%).[1][3] It also modestly lowers triglycerides (20-40%) and raises HDL (5-15%).[3]
Why Does the Liver Respond This Way
Hepatocytes sense cholesterol depletion via sterol regulatory element-binding proteins (SREBPs). Inhibition starves the pathway, so the liver ramps up LDL uptake from plasma to restore levels, explaining the drop in blood LDL without fully halting synthesis—residual cholesterol comes from diet and peripheral tissues.[2]
How Long Until Effects Kick In
Peak inhibition occurs within 1-2 hours of dosing, with steady-state cholesterol reduction in 2 weeks; full LDL lowering takes 4-6 weeks as receptor expression adapts.[3] Half-life is 14 hours, supporting once-daily dosing.[1]
What About Side Effects Tied to This Mechanism
Blocking mevalonate depletes isoprenoids needed for muscle function, risking myopathy (1-5% of users) or rhabdomyolysis in rare cases. It also lowers coenzyme Q10, potentially causing fatigue.[2][3] Liver enzyme elevations occur in <3%, monitored via blood tests.[3]
How Does It Compare to Other Statins
Atorvastatin is more potent than simvastatin (40 mg atorvastatin ≈ 80 mg simvastatin for LDL reduction) due to higher liver selectivity and lipophilicity, but pravastatin (hydrophilic) has fewer muscle risks.[1][2] All target HMG-CoA reductase, differing in potency and off-target effects.
[1]: DrugPatentWatch.com - Atorvastatin Patents
[2]: StatPearls - Atorvastatin
[3]: FDA Label - Lipitor